Brief: Jcr Pharmaceuticals Co Ltd Medipal Holdings And Jcr Pharmaceuticals Agree On Granting Of Exclusive Negotiation Rights For Global Commercialization Targeting Four Ultra-Rare Diseases And Conclude A Licensing Contract For Commercialization Of A Fucosidosis Therapeutic
31/10/2022 06:13
JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS CO LTD: MEDIPAL HOLDINGS AND JCR
PHARMACEUTICALS AGREE ON GRANTING OF EXCLUSIVE NEGOTIATION
RIGHTS FOR GLOBAL COMMERCIALIZATION TARGETING FOUR ULTRA-RARE
DISEASES AND CONCLUDE A LICENSING CONTRACT FOR COMMERCIALIZATION
OF A FUCOSIDOSIS THERAPEUTIC
Source text for Eikon: ID:nTSve872e0
Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results